Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 8/2021

01-08-2021 | Hepatocellular Carcinoma | Special Section: HCC Treatment

Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma

Authors: Zersenay Alem, Timothy E. Murray, Csilla Egri, John Chung, David Liu, Khaled M. Elsayes, Silvia D. Chang, Alison Harris

Published in: Abdominal Radiology | Issue 8/2021

Login to get access

Abstract

Transarterial radioembolization with yttrium-90 microspheres is an established therapy for hepatocellular carcinoma. Post-procedural imaging is important for the assessment of both treatment response and procedural complications. A variety of challenging treatment-specific imaging phenomena complicate imaging assessment, such as changes in tumoral size, tumoral and peritumoral enhancement, and extrahepatic complications. A review of the procedural steps, emerging variations, and timelines for post-treatment tumoral and extra-tumoral imaging changes are presented, which may aid the reporting radiologist in the interpretation of post-procedural imaging. Furthermore, a description of post-procedural complications and their significance is provided.
Literature
1.
2.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001 Sep;35(3):421–30.
3.
Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011 Mar;53(3):1020–2.PubMedCrossRef
4.
Riaz A. Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma. JAMA. 2010 Mar 17;303(11):1062.PubMedPubMedCentralCrossRef
5.
Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, et al. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Clin Med. 2019 Jan 7;8(1):55.PubMedCentralCrossRef
6.
Joo I, Kim H-C, Kim GM, Paeng JC. Imaging Evaluation Following 90 Y Radioembolization of Liver Tumors: What Radiologists Should Know. Korean J Radiol. 2018;19(2):209.PubMedPubMedCentralCrossRef
7.
Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016 Dec;151(6):1155-1163.e2.
8.
Zarva A, Mohnike K, Damm R, Ruf J, Seidensticker R, Ulrich G, et al. Safety of Repeated Radioembolizations in Patients with Advanced Primary and Secondary Liver Tumors and Progressive Disease After First Selective Internal Radiotherapy. J Nucl Med. 2014 Mar 1;55(3):360–6.PubMedCrossRef
9.
Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, et al. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021 Mar 1;94(1119):20200752.PubMedCrossRefPubMedCentral
10.
11.
Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol. 2007 May;68(1):13–23.CrossRef
12.
Kallini JR, Gabr A, Thorlund K, Balijepalli C, Ayres D, Kanters S, et al. Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review. Cardiovasc Intervent Radiol. 2017 Jul 1;40(7):1033–43.PubMedCrossRef
13.
Bozkurt MF, Salanci BV, Uğur Ö. Intra-Arterial Radionuclide Therapies for Liver Tumors. Semin Nucl Med. 2016 Jul;46(4):324–39.PubMedCrossRef
14.
15.
16.
17.
Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Kulik L, et al. Radioembolization with 90 Y Microspheres: Angiographic and Technical Considerations. Cardiovasc Intervent Radiol. 2007 Jul 1;30(4):571–92.PubMedCrossRef
18.
Malhotra A, Liu DM, Talenfeld AD. Radiation Segmentectomy and Radiation Lobectomy: A Practical Review of Techniques. Tech Vasc Interv Radiol. 2019 Jun;22(2):49–57.PubMedCrossRef
19.
Uliel L, Royal HD, Darcy MD, Zuckerman DA, Sharma A, Saad NE. From the Angio Suite to the -Camera: Vascular Mapping and 99mTc-MAA Hepatic Perfusion Imaging Before Liver Radioembolization--A Comprehensive Pictorial Review. J Nucl Med. 2012 Nov 1;53(11):1736–47.PubMedCrossRef
20.
Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013 Mar;57(3):1078–87.PubMedCrossRef
21.
Puranik AD, Rangarajan V, Gosavi A, Shetty N, Gala K, Kulkarni S, et al. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization. Nucl Med Commun [Internet]. 2020 Dec 9 [cited 2021 Mar 31];Publish Ahead of Print. Available from: https://​journals.​lww.​com/​10.​1097/​MNM.​0000000000001334​
22.
Son MH, Ha LN, Bang MH, Bae S, Giang DT, Thinh NT, et al. Diagnostic and prognostic value of 99mTc-MAA SPECT/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image. Sci Rep. 2021 Dec;11(1):3207.PubMedPubMedCentralCrossRef
23.
Mirka H, Duras P, Baxa J, Korcakova E, Ferda J. Contribution of Computed Tomographic Angiography to Pretreatment Planning of Radio-embolization of Liver Tumors. Anticancer Res. 2018 Jul;38(7):3825–9.PubMedCrossRef
24.
Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther. 2016;33:699–714.PubMedPubMedCentralCrossRef
25.
Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009 Apr;49(4):1185–93.PubMedCrossRef
26.
Mora RA, Ali R, Gabr A, Abouchaleh N, Asadi AA, Kallini JR, et al. Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. Abdom Radiol. 2018 Jul;43(7):1723–38.CrossRef
27.
Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, et al. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging. 2021 Jan;102(1):35–44.PubMedCrossRef
28.
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011 Dec;55(6):1309–16.PubMedCrossRef
29.
Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib: Vouche et al. Hepatology. 2013 Nov;58(5):1655–66.
30.
Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, et al. Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. Curr Oncol. 2021 Feb 21;28(1):965–77.PubMedPubMedCentralCrossRef
31.
32.
Mohamed M, Katz AW, Tejani MA, Sharma AK, Kashyap R, Noel MS, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2016 Jan;1(1):35–42.PubMedCrossRef
33.
Bester L, Hobbins PG, Wang S, Salem R. Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer: Imaging findings after 90Y microsphere SIRT. J Med Imaging Radiat Oncol. 2011 Apr;55(2):111–8.PubMedCrossRef
34.
Miller FH, Keppke AL, Reddy D, Huang J, Jin J, Mulcahy MF, et al. Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET. Am J Roentgenol. 2007 Mar;188(3):776–83.CrossRef
35.
Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, et al. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver. 2020 Nov 15;14(6):765–74.
36.
Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology. 2010 Jan;138(1):52–64.PubMedCrossRef
37.
Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, et al. Multimodality Imaging Following 90 Y Radioembolization: A Comprehensive Review and Pictorial Essay. RadioGraphics. 2008 Jan;28(1):81–99.PubMedCrossRef
38.
Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, et al. Imaging of Hepatocellular Carcinoma After Treatment with Yttrium-90 Microspheres. Am J Roentgenol. 2007 Mar;188(3):768–75.CrossRef
39.
Semaan S, Makkar J, Lewis S, Chatterji M, Kim E, Taouli B. Imaging of Hepatocellular Carcinoma Response After 90 Y Radioembolization. Am J Roentgenol. 2017 Nov;209(5):W263–76.CrossRef
40.
Spina JC, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R. Expected and Unexpected Imaging Findings after 90 Y Transarterial Radioembolization for Liver Tumors. RadioGraphics. 2019 Mar;39(2):578–95.PubMedCrossRef
41.
42.
Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation. J Hepatol. 2011 Apr;54(4):695–704.PubMedCrossRef
43.
Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):580–3.PubMedCrossRef
44.
Kallini JR, Miller FH, Gabr A, Salem R, Lewandowski RJ. Hepatic imaging following intra-arterial embolotherapy. Abdom Radiol. 2016 Apr;41(4):600–16.CrossRef
45.
Song JE, Jung KS, Kim DY, Song K, Won JY, Lee HW, et al. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Int J Radiat Oncol. 2017 Oct;99(2):396–406.CrossRef
46.
Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, et al. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma: HEPATOBILIARY MALIGNANCIES. Hepatology. 2015 Oct;62(4):1111–21.PubMedCrossRef
47.
Choi H, Charnsangavej C, Faria S de C, Tamm EP, Benjamin RS, Johnson MM, et al. CT Evaluation of the Response of Gastrointestinal Stromal Tumors After Imatinib Mesylate Treatment: A Quantitative Analysis Correlated with FDG PET Findings. Am J Roentgenol. 2004 Dec;183(6):1619–28.
48.
Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, et al. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma. Oncol Lett. 2013 Dec;6(6):1707–12.PubMedPubMedCentralCrossRef
49.
Kaplan E, Kaplan S. Computed tomographic perfusion imaging for the prediction of response transarterial radioembolization with Yttrium‑90 glass microspheres of hepatocellular carcinoma. :10.
50.
Kokabi N, Camacho JC, Xing M, Qiu D, Kitajima H, Mittal PK, et al. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Abdom Imaging. 2014 Oct 1;39(5):969–78.PubMedCrossRef
51.
52.
Hectors SJ, Lewis S, Kennedy P, Bane O, Said D, Segall M, et al. Assessment of Hepatocellular Carcinoma Response to 90 Y Radioembolization Using Dynamic Contrast Material–enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging. Radiol Imaging Cancer. 2020 Jul 1;2(4):e190094.PubMedPubMedCentralCrossRef
53.
53. Mendiratta-Lala M, Masch WR, Shampain K, Zhang A, Jo AS, Moorman S, et al. MRI Assessment of Hepatocellular Carcinoma after Local-Regional                    Therapy: A Comprehensive Review. Radiol Imaging Cancer. 2020 Jan 1;2(1):e190024.PubMedPubMedCentralCrossRef
54.
Ibrahim SM, Nikolaidis P, Miller FH, Lewandowski RJ, Ryu RK, Sato KT, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging. 2009 Sep;34(5):566–81.PubMedCrossRef
55.
Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, et al. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol. 2020 Oct 27;12(10):738–53.PubMedPubMedCentralCrossRef
56.
Amin P, Ness J, Brown M, Sullivan I. Deciphering Liver Imaging After Interventional Oncology Treatments for Hepatocellular Carcinoma. Contemp Diagn Radiol. 2021 Mar 31;44(7):1–7.CrossRef
57.
Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, et al. Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres. Dig Dis Sci. 2008 Sep;53(9):2556–63.PubMedCrossRef
58.
Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization. Ann Surg Oncol. 2009 Jun;16(6):1587–96.PubMedCrossRef
59.
Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, et al. 90 Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes: Liver Resection After 90 Y Radiation Lobectomy. J Surg Oncol. 2016 Jul;114(1):99–105.PubMedCrossRef
60.
Singh P, Anil G. Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imaging. 2013;13(4):645–57.CrossRef
61.
Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary Sequelae following Radioembolization with Yttrium-90 Microspheres. J Vasc Interv Radiol. 2008 May;19(5):691–7.PubMedCrossRef
62.
Korkmaz M, Bozkaya H, Çınar C, Şanal B, Güneyli S, Parıldar M, et al. Liver abscess following radioembolization with yttrium-90 microspheres. Wien Klin Wochenschr. 2014 Dec;126(23–24):785–8.PubMedCrossRef
63.
Mascarenhas N, Ryu R, Salem R. Hepatic Radioembolization Complicated by Abscess. Semin Interv Radiol. 2011 Jun;28(02):222–5.CrossRef
64.
Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: Description and possible risk factors. Cancer. 2008 Apr 1;112(7):1538–46.PubMedCrossRef
65.
66.
Sugi MD, Menias CO, Lubner MG, Bhalla S, Mellnick VM, Kwon MH, et al. CT Findings of Acute Small-Bowel Entities. RadioGraphics. 2018 Sep 1;38(5):1352–69.PubMedCrossRef
67.
Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal Complications Associated with Hepatic Arterial Yttrium-90 Microsphere Therapy. J Vasc Interv Radiol. 2007 Apr;18(4):553–61.PubMedCrossRef
68.
Kothari S, Li Y, Almouradi T, Berkelhammer C. Radiation Gastritis Associated With Yttrium-90 Microsphere Radioembolization: 2647. Off J Am Coll Gastroenterol ACG. 2018 Oct;113:S1472.CrossRef
69.
Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review. J Vasc Interv Radiol. 2009 Sep;20(9):1121–30.PubMedCrossRef
70.
Lam MGEH, Banerjee S, Louie JD, Abdelmaksoud MHK, Iagaru AH, Ennen RE, et al. Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol. 2013 Dec;36(6):1536–47.PubMedCrossRef
71.
Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, et al. Gastroduodenal Injury After Radioembolization of Hepatic Tumors. Am J Gastroenterol. 2007 Jun;102(6):1216–20.PubMedCrossRef
72.
Naymagon S, Warner RRP, Patel K, Harpaz N, Machac J, Weintraub JL, et al. Gastroduodenal Ulceration Associated with Radioembolization for the Treatment of Hepatic Tumors: An Institutional Experience and Review of the Literature. Dig Dis Sci. 2010 Sep;55(9):2450–8.PubMedCrossRef
73.
74.
75.
Tann M, Haste P, Rice M. Do we still need to assess for lung shunt in all Y90 Liver treatment’s ? J Nucl Med. 2019 May 1;60(supplement 1):1315–1315.
76.
Das A, Riaz A, Gabr A, Ali R, Mora R, Al Asadi A, et al. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):807–15.PubMedCrossRef
77.
Kwok N, Irani Z, Sheth R, Arellano RS. Hepatopulmonary shunt reduction with bland embolization for yttrium-90 radioembolization. Diagn Interv Imaging. 2016 Mar 1;97(3):369–70.PubMedCrossRef
78.
Schiro BJ, Amour ESt, Harnain C, Gandhi RT. Management of High Hepatopulmonary Shunts in the Setting of Y90 Radioembolization. Tech Vasc Interv Radiol. 2019 Jun 1;22(2):58–62.
79.
Thüring J, Zimmermann M, Bruners P, Pedersoli F, Schulze-Hagen M, Barzakova E, et al. Short-Term Oral Sorafenib for Therapy of Intratumoral Shunts of Hepatocellular Carcinoma to Enable Intraarterial Treatment. Cardiovasc Intervent Radiol. 2019 Oct 1;42(10):1494–9.PubMedPubMedCentralCrossRef
80.
Wright CL, Werner JD, Tran JM, Gates VL, Rikabi AA, Shah MH, et al. Radiation Pneumonitis Following Yttrium-90 Radioembolization: Case Report and Literature Review. J Vasc Interv Radiol. 2012 May;23(5):669–74.PubMedCrossRef
81.
82.
Sangro B, Martínez‐Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P, et al. Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. Hepatology. 2017;66(3):969–82.PubMedCrossRef
Metadata
Title
Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma
Authors
Zersenay Alem
Timothy E. Murray
Csilla Egri
John Chung
David Liu
Khaled M. Elsayes
Silvia D. Chang
Alison Harris
Publication date
01-08-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 8/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-03095-8

Other articles of this Issue 8/2021

Abdominal Radiology 8/2021 Go to the issue

Review

Cross-sectional imaging features of unusual adrenal lesions: a radiopathological correlation

S.I. : HCC Treatment

HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy

Special Section: HCC Treatment

LI-RADS treatment response lexicon: review, refresh and resolve with emerging data

Correction

Correction to: Artificial intelligence in assessment of hepatocellular carcinoma treatment response

Special Section : HCC Treatment

Role of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow

Special Section: Rectal Cancer

Preoperative evaluation of extramural venous invasion in rectal cancer using radiomics analysis of relaxation maps from synthetic MRI

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits